|
Type |
Source |
| 3 |
Revue |
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
| 36 |
Revue |
Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC.
Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods.
Am J Health-Syst Pharm 1995 ; 52: 2423-2426. |
| 58 |
Revue |
Parker WA.
Physical compatibility of ranitidine HCl with preoperative injectable medications.
Can J Hosp Pharm 1985 ; 38: 160-161. |
| 73 |
Revue |
Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159. |
| 81 |
Revue |
Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678. |
| 84 |
Revue |
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499. |
| 93 |
Revue |
Hutchings SR, Rusho WJ, Tyler LS.
Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery.
Am J Health-Syst Pharm 1996 ; 53: 2185-2188. |
| 99 |
Revue |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 103 |
Revue |
Erickson SH, Ulici D.
Incompatibility of cefotetan disodium and promethazine hydrochloride.
Am J Health-Syst Pharm 1995 ; 52: 1347. |
| 106 |
Revue |
Scott SM.
Incompatibility of cefoperazone and promethazine.
Am J Hosp Pharm 1990 ; 47: 519. |
| 124 |
Revue |
Abubakar AA, Mustapha A, Wambebe OC.
An in vitro interaction between promethazine hydrochloride and chloroquine phosphate.
Int Pharm J 1993 ; 7: 14-19. |
| 169 |
Revue |
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363. |
| 182 |
Revue |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 244 |
Revue |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 249 |
Revue |
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 251 |
Revue |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
| 253 |
Revue |
Trissel LA, Chandler SW, Folstad JT.
Visual compatibility of amsacrine with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 2525-2528. |
| 288 |
Revue |
Cervenka P, Dejong DJ, Butler BL, Monzingo MD.
Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration.
Hosp Pharm 1992 ; 27: 957-958,961-962. |
| 299 |
Revue |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
| 301 |
Revue |
Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
| 307 |
Revue |
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 334 |
Revue |
Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992. |
| 335 |
Revue |
Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406. |
| 350 |
Revue |
Martens HJ, De Goede PN, Van Loenen AC.
Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers.
Am J Hosp Pharm 1990 ; 47: 369-373. |
| 404 |
Revue |
Forman JK, Souney PF.
Visual compatibility of midazolam hydrochloride with common preoperative injectable medications.
Am J Hosp Pharm 1987 ; 44: 2298-2299. |
| 476 |
Revue |
Knapp AJ, Mauro VF, Alexander KS.
Incompatibility of ketorolac tromethamine with selected postoperative drugs.
Am J Hosp Pharm 1992 ; 49: 2960-2962. |
| 492 |
Revue |
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189. |
| 496 |
Revue |
Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746. |
| 518 |
Revue |
Jimenez MD.
Visual compatibility of nalbuphine hydrochloride and promethazine hydrochloride.
Am J Hosp Pharm 1988 ; 45: 1278. |
| 616 |
Revue |
Jump WG, Plaza VM, Poremba A.
Compatibility of nalbuphine hydrochloride with other preoperative medications.
Am J Hosp Pharm 1982 ; 39: 841-843. |
| 795 |
Revue |
Henderson F.
21-day compatibility of hydromorphone hydrochloride and promethazine hydrochloride in a cassette.
Am J Health-Syst Pharm 1996 ; 53: 2338-2339. |
| 905 |
Revue |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 921 |
Revue |
Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292. |
| 1069 |
Revue |
Peek BT, Webster KD, Da Camara CC.
Stability and compatibility of promethazine hydrochloride and dihydroergotamine mesylate in combination.
Am J Health-Syst Pharm 1999 ; 56: 1835-1838. |
| 1200 |
Revue |
Chaudry IA, Bruey KP, Hurlburt LE, Oden EM.
Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives.
Am J Hosp Pharm 1981 ; 38: 1737-1742. |
| 1228 |
Revue |
Allen LV, Stiles ML.
Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2.
Am J Hosp Pharm 1981 ; 38: 380-381. |
| 1232 |
Revue |
Beatson C, Taylor A.
A physical compatibility study of furosemide & flucloxacillin injections.
Br J Pharm Pract 1987 ; 9: 223-226, 236. |
| 1410 |
Revue |
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1415 |
Revue |
Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74. |
| 1423 |
Revue |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1438 |
Revue |
Souney PF, Solomon MA, Stancher D.
Visual compatibility of cimetidine hydrochloride wih common preoperative injectable medications.
Am J Hosp Pharm 1984 ; 41: 1840-1841. |
| 1496 |
Revue |
Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428. |
| 1625 |
Revue |
Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321. |
| 1662 |
Revue |
Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37. |
| 1712 |
Revue |
Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233. |
| 1713 |
Revue |
Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315. |
| 1721 |
Revue |
Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72. |
| 1739 |
Revue |
Scott SM.
Incompatibility of cefperazone and promethazine.
Am J Health-Syst Pharm 1990 ; 47: 519. |
| 1754 |
Revue |
Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244. |
| 1803 |
Revue |
Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85. |
| 1925 |
Revue |
Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519. |
| 1953 |
Revue |
Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
| 2087 |
Revue |
Ferreira E, Forest JM, Hildgen P.
Compatibility of dimenhydrinate injectable by Y administration.
Pharmactuel 2004 ; 37: 17-20. |
| 2109 |
Revue |
Pelletier E, Forest JM, Hildgen P.
Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels.
Pharmactuel 2006 ; 39: 71-75. |
| 2179 |
Revue |
Trusley C, Ben M, Kupiec TC, Trissel LA.
Physical and chemical stability of palonosetron with metoclopramide and promethazine during simulated Y-site administration.
Int J Pharm Compound 2007 ; 11, 1: 82-85. |
| 2269 |
Revue |
Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |
| 3012 |
Revue |
Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220. |
| 3216 |
Revue |
Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18 |
| 3249 |
Revue |
Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
| 3408 |
Revue |
Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21. |
| 3531 |
Laboratoire |
Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics
Wockhardt 2014 |
| 3539 |
Laboratoire |
Bivalirudin (Angiox®) - Summary of Product Characteristics.
The Medecines Company 2013 |
| 3540 |
Laboratoire |
Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010 |
| 3585 |
Laboratoire |
Benzylpenicillin sodium - Summary of Product Characteristics
Genus Pharmaceuticals 2008 |
| 3593 |
Laboratoire |
Ketorolac trometamol (Ketorolac®) - Summary of Product Characteristics
Beacon Pharmaceuticals 2011 |
| 3599 |
Laboratoire |
Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics
Amco Amdipharm Mercry 2013 |
| 3637 |
Laboratoire |
Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics
Hameln Pharmaceuticals 2014 |
| 3672 |
Laboratoire |
Nalbuphine Mylan - Résumé des caractéristiques du produit
Mylan SAS 2016 |
| 3674 |
Laboratoire |
Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016 |
| 3675 |
Laboratoire |
Thiopental sodium - Summary of Product Characteristics
Archimedes Pharma UK Ltd 2015 |
| 3767 |
Revue |
Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172. |
| 3964 |
Revue |
Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33. |
| 4650 |
Laboratoire |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021 |
